|Day's Range||0.1000 - 0.1000|
As of June 21, Altria was trading at a forward PE ratio of 11.1x—compared to 12.8x before its first-quarter earnings were announced. Altria posted its first-quarter earnings on April 25.
Scott Gottlieb’s comments might have led to a fall in Altria’s stock price on June 21. At the closing on June 21, the company was trading at $48.00—a fall of 4.5% from the previous day’s closing price.
fell Friday after a former Food and Drug Administration commissioner expressed doubts about whether e-cigarette producer Juul would see the agency clear its products for continued sale. Richmond, Va.-based Altria holds 35% of Juul, the San Francisco producer of e-cigarettes, which contain a battery, heating element and a nicotine-infused liquid. "Juul is in a hard spot to ever get their product approved," Scott Gottlieb told CNBC's "Squawk Box" in an interview.
(Bloomberg) -- The former commissioner of the Food and Drug Administration said he thinks Juul Labs Inc. will have a difficult time getting its e-cigarette approved under rules that will eventually force makers of the devices to go through government review to keep selling to consumers.“Juul is going to be in a hard spot to ever get their product approved,” ex-Commissioner Scott Gottlieb, who stepped down from leading the agency earlier this year, said on CNBC Friday.Altria Group Inc., which sells Marlboro cigarettes, bought a $12.8 billion stake in Juul last year. Shares of the tobacco company closed down 4.5% to $48 in New York, the lowest closing price since Jan. 30.During his two-year tenure atop the FDA, Gottlieb initially took a cautious approach toward strictly regulating e-cigarettes, seeing them as a tool to help adult smokers quit. He evolved into a harsh critic, calling youth use an “epidemic” and said that Juul and other e-cigarettes had attracted previous nonsmokers.To respond to a lawsuit claiming the agency failed to sufficiently regulate the products, the FDA has proposed giving manufacturers 10 months to submit applications to keep selling the nicotine devices.Juul said it's working on its application to the FDA, which will include information on how the product can help existing smokers stop using cigarettes. ``We are confident adult smokers will not be left without a viable alternative to combustible cigarettes,'' said Juul spokesman Matt David.Juul is popular with many young and underage people, and public health advocates have said that the company specifically targeted younger users. The company has pulled back on some marketing activities and has taken steps to make sure its product reaches only people of appropriate age. Juul’s website says that “We don’t want anyone who doesn’t smoke, or already use nicotine, to use Juul products.”“We remain confident that Juul can successfully navigate the PMTA process,” Altria spokesman Steven Callahan said in an emailed statement. PMTA refers to the FDA’s premarket tobacco application rules. A federal judge said last month the FDA must speed up its implementation of the rules, though hasn’t made a final ruling on the agency’s proposal.A spokesman for the FDA didn’t immediately provide a comment.Government health officials are also researching the use of Juul as part of a regular survey that gauges youth tobacco use. The data they collect could have an impact on the likely review of the devices.“If we see a further increase in overall use, and respondents report to using Juul mostly, then we think whatever Juul says, and whatever actions they point to that they have implemented, it won’t matter,” Ryan Tomkins, a stock analyst with Jefferies, said in a note to clients Friday.(Adds Juul statement in sixth paragraph)\--With assistance from Janet Freund, Tiffany Kary and Anna Edney.To contact the reporter on this story: Drew Armstrong in New York at email@example.comTo contact the editors responsible for this story: Drew Armstrong at firstname.lastname@example.org, Timothy AnnettFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Declining cigarette sales and volumes continue to pressure large tobacco companies. To combat falling tobacco demand, industry giant Altria Group, Inc. (MO) has raised its prices six cents per pack, or $3 per carton, according to Wells Fargo analyst Bonnie Herzog, per Barron's. Herzog argues that the move demonstrates Altria's pricing power, adding that British American Tobacco p.l.c.
Altria Group (MO) is a tobacco products giant. Its core tobacco business holds the flagship Marlboro cigarette brand, explains income expert Ben Reynolds, editor of Sure Retirement.
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Altria Group Inc NYSE:MOView full report here! Summary * Perception of the company's creditworthiness is neutral * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is extremely low for MO with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting MO. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding MO are favorable, with net inflows of $13.20 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Consumer Goods sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swap | NeutralThe current level displays a neutral indicator. Although MO credit default swap spreads are decreasing, they remain near their highest levels of the last 3 years, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Shares of Cronos Group (NASDAQ: CRON) are starting to stabilize. After its weak first-quarter revenue report reminded investors that Cronos stock was very expensive, speculators are buying the shares once again. Why?Cronos has a $7.9 billion market cap but with its quarterly revenue of CAD $6.5 million (USD ~ $5 million or $20 million annualized), the company trades at 154 times sales.InvestorPlace - Stock Market News, Stock Advice & Trading TipsCronos has no room to report any signs of slowing revenue growth in the near-term. It must continue winning supply deals to grow market share. And on May 14, it did just that. The company inked a $30 million multi-year supply deal with MediPharm Labs over 18 months.The deal could optionally extend to $60 million over 24 months. Cronos will secure MediPharm's private label supply of concentrates, after processing Cronos' dry cannabis.The supply deal validates Altria's (NYSE: MO) $1.8 billion investment in Cronos. By outsourcing the process to a secondary player, Cronos may put Altria's cash to better use. Altria outsources its own tobacco production to thousands of farmers and probably advised Cronos to do the same. * 7 Top-Rated Biotech Stocks to Invest In Today Instead of spending all of its resources on building up production facilities, it could land additional partnership deals while sharing risks with them. Cronos is bullish on its partnerships, especially with its work with Ginkgo.In the September 2018 press release, Cronos said, "The landmark partnership between Cronos Group and Ginkgo will leverage the expertise of both organizations to solve this challenge and make more accessible the benefits of cannabinoids in an economically sustainable way."Since then, Ginkgo met its targets, triggering milestone payments. Ginkgo is a leader in synthetic biology, giving Cronos an advantage over the competition as the science works eventually bring meaningful results. Mixed First-Quarter Results and Cronos StockIn the first quarter, ASP (average selling price) rose 7% to $5.73 due to higher revenue from CBD oil. Operating expenses also rose 12%, as Cronos incurred professional fees for services related to its strategic initiatives.Despite the mixed numbers in the period, Cronos enjoys massive cash levels on its balance sheet that negates any investor worry over quarterly results. Altria's backing puts Cronos in a better position to capture opportunities that arise and to accelerate its strategic initiatives.Cronos has four strategic goals. It is establishing a global production footprint, developing a diversified global sales and distribution network, creating disruptive intellectual property, and growing a portfolio of products that resonates with consumers.Since January 2019, Cronos secured listings with a number of private retailers in Canada and in the province of Ontario, British Columbia, Nova Scotia, and Prince Edward Island. Collectively, those five provinces represent 58% of the Canadian population. Cronos Putting Altria Cash to WorkCronos plans to increase its capital investments to support an increase in production. The company expects Peace Naturals ramping up production through the course of 2019. The company has partnerships with companies in Israel, where it is developing a vapor product.Cronos will have additional production capacity ready in the upcoming second half of the year. It had around 1000 kilos of capacity in the first quarter and aims to have 40,000 kilos next. Getting production to that level will depend on how regulations change. Cronos is scaling up output depending on product demand levels, and demand is a function of regulatory changes that open up the market opportunity. Cronos had over $2 billion on its balance sheet in Q1 but is demonstrating restraint in the way it spends that cash. The Bottom Line on Cronos StockCronos is not profitable yet and its market size is still unknown. Though the company is still losing money, its nearly $2 billion cash balance gives the company plenty of M&A opportunities. Analysts are bullish on the company and have an average price of $28.50 on Cronos stock.Disclosure: As of this writing, the author did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * The 7 Best Tech Stocks to Buy for the Second Half of 2019 * 7 Top-Rated Biotech Stocks to Invest In Today * 4 Semiconductor Stocks to Sell Compare Brokers The post After a Bumpy Few Months, Cronos Stock Is Back on the Move appeared first on InvestorPlace.
Is Altria Group Inc (NYSE:MO) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before doing days of research on it. Given their 2 and 20 payment structure, hedge funds have more incentives and resources than the average investor. The funds […]
Wells Fargo argues that Altria’s recent price increases demonstrate the tobacco giant’s pricing power—and its ability to compete even in the face of e-cigarette popularity.
Wells Fargo likes Altria Group Inc (NYSE: MO )’s willingness to use price increases to offset pressure from declining volume in cigarette sales. The Analyst Wells Fargo’s Bonnie Herzog reiterated an Outperform ...
Goldman Sachs has a new strategy for investors to consider. The firm has now revealed that the most dominant companies in an industry tend to outperform companies with a smaller percentage of market sales. There’s even a name for these kind of companies ‘superstar firms.’ “The market positioning of superstar firms often allows for greater bargaining power over consumers and workers and higher profitability,” Goldman's senior US equity strategist David Kostin told investors. “Superstar firms have been one driver of the explosion in US corporate margins post-crisis.”According to Kostin, companies with the highest share of industry sales have returned 49% since 2015. In contrast, companies with the lowest share of industry sales returned just 16% over the same time-frame. Here we take a closer look at five of the most prominent stocks in Goldman Sachs' 'superstar' portfolio. Should you buy into these names now? Let’s see what the Street has to say now… 1\. Altria (MO) * 88% share of industry US salesDuring the last five years, tobacco giant MO has gained 23%. That’s despite a disastrous 2018 which saw prices pullback 30%. So far in 2019, shares are holding steady- and Wells Fargo’s Bonnie Herzog spies upside ahead. She has just reiterated her Buy rating with a price target of $65 (28% upside potential). She believes that Altria will be able to weather the shift from traditional cigarettes to vapor products. “Major tobacco manufacturers are well-positioned in the current regulatory/political environment driven by strong management teams and a deep reservoir of bench talent and funds to drive innovation” says the analyst. Interestingly, Herzog adds that industry consolidation “will increasingly favor scale in the global ‘arms’ race in reduced-risk products (RRPs) while addressing the youth crisis.” Altria, for example, recently invested $12.8 billion in leading e-cigarette maker Juul Labs as well as a further $1.8 billion in cannabis stock Cronos Group (CRON). Luckily for Altria, Juul recently revealed Q1 sales of $528 million, up 23% from the previous quarter’s revenue. Now there is talk that Juul could be on the way to opening its own chain of vaping shops, starting in Houston and Dallas, Texas. Meanwhile Altria will also exclusively distribute Philip Morris International's (PM) "heat-not-burn" tobacco device. Called IQOS the device heats tobacco to around 350°C vs temperatures in excess of 600°C for a cigarette. “Because the tobacco is heated and not burned, the levels of harmful chemicals are significantly reduced compared to cigarette smoke” claims the company.Overall, we can see that the stock has a cautiously optimistic Moderate Buy analyst consensus. This is based on all the ratings received by the company over the last three months. Meanwhile the average analyst price target of $60 indicates upside potential of 18% from current levels. View MO Price Target & Analyst Ratings Detail 2\. Alphabet (GOOGL) * 63% share of industry US salesLooking back, GOOGL has almost doubled in value over the last five years. But that doesn’t mean there isn’t further upside potential ahead. GOOGL still retains a bullish ‘Strong Buy’ Street consensus. What’s more, the $1,334 average analyst price target indicates upside potential of over 22%. That’s despite more anti-trust talk from regulators, with Makan Delrahim (Assistant AG, DOJ) suggesting that stricter regulation may be coming.“Investors may be getting relatively comfortable with the underlying regulatory risk given that so far, the financial performance at FB, GOOGL and AMZN continues to be in line or even better than what the Street has been expecting” notes top-rated SunTrust Robinson analyst Youssef Squali. Given the complexity and global considerations of regulating and/or breaking up big tech, Squali is confident that it is likely to take years for regulatory measures to be implemented, and even longer for them to start impacting the financials of these companies. What’s more there is a growing realization that even in case of a break-up of a behemoth like GOOGL, the value of the parts may be higher than the whole over time. For example, Needham analyst Laura Martin has just reiterated her GOOGL buy rating with a $1,350 price target. She has calculated that the company could be worth nearly 50% more than its current valuation in the case of a break-up. Martin values Google search at $600 per Alphabet share, YouTube at $200, and the Android App Store at $100. Plus there are extra contributions from Gmail, Maps, Waymo, DeepMind etc. “Elevated regulatory scrutiny adds costs and margin pressures for 2-4 years, but probably has little impact on revenue growth or consumer usage until outcomes are determined and then fought out in the courts,” she concluded.View GOOGL Price Target & Analyst Ratings Detail 3\. General Electric (GE) * 51% share of industry US sales With new CEO Larry Culp at the helm, General Electric has put on a remarkable year-to-date rally of over 40%. The company was primed for a rebound after plunging over 50% in 2018. And analysts are currently divided about the stock’s outlook going forward.The key question is whether Culp’s multiyear turnaround plan will succeed to boost the company while reducing its massive $110 billion debt pile (as of March 31, according to FactSet). Cowen & Co’s Gautam Khanna sums up the problem here: “The major debates on GE's stock, which won't be resolved for years, are whether cost cutting & portfolio actions will return Industrial to sustained high FCF [free cash flow] conversion, & if Capital will require more cash support.” As a result, the analyst reiterates his Hold rating on GE with an $8 price target. That suggests shares could fall 20% from current levels. However, there are some more positive voices in the crowd. Most noticeably, William Blair’s Nicholas Heymann has just reiterated his GE Buy rating. He believes GE can ‘materially outperform’ the market over the next 12 months.“We continue to believe GE’s underlying intrinsic value (with no value assigned to Power) is somewhere in the range of $14-$16 per share,” the analyst revealed, describing this as a “highly feasible base-case valuation for GE’s share price over the next 6-12 months.”“The unbridled fear that overshadowed a rational assessment of the company’s underlying fair value exiting 2018 is beginning to recede and be replaced with far less ambiguous and more tangible plans and actions that will support a likely materially higher value for GE’s stock over the next 12 months and beyond,” said Heymann. View GE Price Target & Analyst Ratings Detail 4\. Walt Disney (DIS) * 49% share of industry US salesThis is a critical year for Walt Disney. As well as two new Star Wars attractions, DIS is also launching its own direct-to-consumer (DTC) streaming service known as Disney+. Clearly investors are feeling optimistic- boosted by the success of Avengers: Endgame (the second highest-grossing film of all time), shares are up 29% year-to-date. This brings Walt Disney’s total five-year gain of over 70%. It’s not just investors that are bullish on DIS right now. In the last three months, 16 analysts have published DIS Buy ratings vs just 3 Hold ratings. That gives DIS its ‘Strong Buy’ Street consensus. Meanwhile the average analyst price target of $153 indicates upside potential of 8%. “I believe that Disney+ will be a significant revenue driving opportunity along with the ongoing success of Disney Studios and Theme Parks” commented five-star Tigress Financial analyst Ivan Feinseth. “I further believe both Star Wars and Marvel franchises including a number of series from both these franchises will be significant drivers for Disney+ subscriptions,” Feinseth wrote. ‘Star Wars Episode IX: The Rise of Skywalker’ is set for release this December, and could also generate a whopping $2 billion in box office revenue.At the same time Morgan Stanley’s Benjamin Swinburne has just raised Disney’s long-term DTC subscribers and earnings estimates. This leads him to a new $160 price target and $210 bull case. He is now forecasting over 130mm global OTT subscribers by 2024, and is confident that DIS shares can sustain a premium multiple as the service ramps up. The analyst’s willingness to underwrite these higher estimates stems from: 1) A faster-than-expected global launch for Disney+; 2) More IP aggregating more quickly than anticipated; and 3) A plan to leverage third-party distribution. View DIS Price Target & Analyst Ratings Detail 5\. General Motors (GM) * 48% share of industry US salesOnly three analysts have published recent ratings on GM. Two analysts are staying neutral on the stock, while one analyst- Morgan Stanley’s Adam Jonas\- has a bullish rating on GM. Encouragingly, out of the three analysts, Jonas is the analyst with the strongest stock picking track record. Following relatively ‘in-line’ Q1 earnings results, Jonas reiterated his buy rating and Street-high price target of $44. From current levels that translates into 23% upside potential. According to the analyst, Q1 earnings didn’t fundamentally change his take on the GM story- especially if you strip away the mark-to-market ‘noise’ from the Lyft (LYFT) and PSA revaluations. Nonetheless, Jonas revealed that he was "sympathetic to some investor profit taking" after prices climbed 5% in April.And the analyst also moved to temper expectations surrounding GM’s self-driving Cruise unit. "While we think GM Cruise has important technological value, we urge investors to lower expectations on revenue generation and profitability of the unit," Jonas advised. "Taking nothing away from GM cruise, it is our understanding that the technology required to remove human drivers at an acceptable level of consumer safety is likely many years away." He continued: "And the legal and regulatory construct to support, even proven technology, may present even greater hurdles largely outside of GM Cruise's control."At the time of writing, General Motors has enjoyed a modest year-to-date rise of 7%. Despite rallying in both 2016, and 2017, 2018 was a more difficult year for GM investors with the stock losing 19%. View GM Price Target & Analyst Ratings DetailDiscover stock ideas from the Street’s best performing analysts here
Vape-maker Juul hits back on San Fran's unanimous vote to ban e-cigarette sales over underage vaping concerns. Yahoo Finance's Zack Guzman & Kristin Myers, along with NY Post Hedge Fund reporter Carleton English discuss with Stanford University Professor Dr. Robert Jackler.
Stocks are once again soaring despite calls for greater market volatility. The S&P 500 touched new intraday highs today. Mark Devaul, Hennessy Equity and Income Fund Equity portfolio manager.
Akerna, a company that provides compliance software to the cannabis industry, headed to the Nasdaq today under the ticker KERN and the backing of an early Facebook investor. Yahoo Finance's Dan Roberts, Heidi Chung and Myles Udland speak to Akerna CEO Jessica Billingsley.